Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction

22 Jun 2021

Abstract excerpt

are found in approximately 30% of human cancers, resulting in the delivery of a persistent signal to critical downstream effectors that drive tumorigenesis. RAS-driven malignancies respond poorly to conventional cancer treatments and inhibitors that target RAS directly are limited; therefore, the identification of new strategies and/or drugs to disrupt RAS signaling in tumor cells remains a pressing therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Melanoma and MAPK Pathways
Share to Microbial Natural Products and Biosynthesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34158349
DOI: 10.1158/1535-7163.mct-21-0175

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF InteractionPMID 34158349Read ↗

BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.Semantic proximity Read ↗

Small-molecule modulation of Ras signaling.Semantic proximity Read ↗

Small-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven CancersSemantic proximity Read ↗

Inhibition of Ras for cancer treatment: the search continues.Semantic proximity Read ↗

Probing RAS Function Using Monobody and NanoBiT Technologies.Semantic proximity Read ↗

Live-cell microscopy reveals small molecule inhibitor effects on MAPK pathway dynamics.Semantic proximity Read ↗

Protomer Selectivity of RAF Inhibitors Within the RAS/RAF SignalosomeSemantic proximity Read ↗

The RAS-Effector Interaction as a Drug Target.Semantic proximity Read ↗

A subset of flavaglines inhibits KRAS nanoclustering and activation.Semantic proximity Read ↗

Competitive Inhibitors of Ras Effector BindingSemantic proximity Read ↗

Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.Semantic proximity Read ↗

Selective Targeting of Ras Mutant Cancers via a New Small MoleculeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.